

S/N: 10/507,046



ITW
1642
PATENT

Confirmation No. 8798

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SCHLEBUSCH, et al.	Examiner:	Unassigned
Serial No.:	10/507,046	Group Art Unit:	1641
Filing Date	September 9, 2005	Docket:	14836-46758
Title:	SPECIFIC AB1'-ANTIBODIES AGAINST TUMOUR ASSOCIATED ANTIGEN CA 125		

CERTIFICATE UNDER 37 CFR 1.8 The undersigned hereby certifies that this Transmittal Letter and the papers, as described herein, are being deposited via First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on January 26, 2006.

By: 

Tim Tingkang Xia

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CUSTOMER NO. 24728

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet containing Certificate of Mailing (1 page)
- ☒ Information Disclosure Statement (37 C.F.R. § 1.97(b)) (2 pages)
- ☒ Form PTO-1449 Listing 4 References (2 pages)
- ☒ Copies of Three (3) Non-US References (59 pages)
- ☒ Return postcard

MORRIS, MANNING & MARTIN, LLP
1600 Atlanta Financial Center
3343 Peachtree Road NE
Atlanta, Georgia 30326
404.495.3678
Customer No. 24728

By: 

Name: Tim Tingkang Xia
Reg. No.: 45,242
TX

S/N: 10/507,046



PATENT
Confirmation No. 8798

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SCHLEBUSCH, et al.	Examiner:	Unassigned
Serial No.:	10/507,046	Group Art Unit:	1641
Filing Date	September 9, 2005	Docket:	14836-46758
Title:	SPECIFIC AB1'-ANTIBODIES AGAINST TUMOUR ASSOCIATED ANTIGEN CA 125		

CERTIFICATE UNDER 37 CFR 1.8 The undersigned hereby certifies that this Transmittal Letter and the papers, as described herein, are being deposited via First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on January 26, 2006.

By: 
Tim Tingkang Xia

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CUSTOMER NO. 24728

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each non-U.S. patent document or other information listed on the enclosed Form 1449 is provided herewith, if applicable.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Respectfully submitted,

MORRIS, MANNING & MARTIN, LLP

January 26, 2006



Tim Tingkang Xia

Attorney for the Applicant on the Record

Reg. No.: 45,242

Morris, Manning & Martin, LLP
1600 Atlanta Financial Center
3343 Peachtree Road, N.E.
Atlanta, Georgia 30326-1044
Telephone: 404.233.7000
Customer No. 24728

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/507,046
		Filing Date	September 9, 2005
		First Named Inventor	Harald Schlebusch et al.
		Art Unit	1641
		Examiner Name	Unassigned
Sheet 2	of 2	Attorney Docket Number	14836-46758

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	SCHULTES, B. et al.; "Anti-idiotypic induction therapy: Anti-CA125 antibodies (AB3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)"; Cancer Immunology and Immunotherapy; June 1998; pp. 201-212; Vol. 46, No. 4.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.